OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense ribonucleic acid (RNA) pneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. RSV can cause upper respiratory tract infections (the common cold) and is the most important cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, in infants. RSV is also an important cause of hospitalizations and deaths in elderly adults.

Today, Medimmune’s Synagis (palivizumab) is the only licensed intervention for the prevention of RSV in infants at a high risk of severe infection. This humanized, mouse monoclonal antibody (mAb) was first approval in 1998, and while it is an efficacious prophylactic intervention, its short 20-day half-life necessitates monthly dosing during the RSV season. Moreover, the high cost of Synagis limits its use to certain subgroups of infants who are at high risk of severe RSV infection, and it is not indicated for use in elderly adults, leaving a key population of high-risk individuals unprotected. Furthermore, due to the absence of effective RSV-specific antivirals, the treatment of RSV infections is largely restricted to a number of supportive treatment options. GlobalData projects the global RSV marketplace — which, for the purposes of this report, comprises the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, Japan) — to experience unprecedented growth from 2014–2024, driven by the arrival of novel approaches to prevention and management of RSV.


Overview of RSV infections, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline RSV market revenue from 2014–2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting RSV product sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global RSV market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the RSV marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2014–2024)?

What research and development (R&D) strategies will companies leverage to compete in the future RSV marketplace?

Which patient population(s) are most likely to be targeted by novel RSV prophylactic and therapeutic agents?

What clinical and commercial factors are likely to influence RSV product uptake in the 7MM?

Janssen (Johnson & Johnson)
Gilead Sciences
*All listed companies have at least 1 product included in GlobalData’s epidemiology-based, 10-year drug sales forecast model.

Other Companies Mentioned
Ark Biosciences
Biota Pharmaceuticals
Romark Laboratories
Spring Bank Pharmaceuticals
Immunovaccine, Inc.
Bavarian Nordic
Meda Pharmaceuticals

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures



2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology



3.2Symptoms and Prognosis



3.3Quality of Life

3.4Disease Management

3.4.1Diagnosis of RSV Infection

3.4.2Prevention of RSV Infection

3.4.3Treatment of RSV Infection


4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1Preterm Infants and Children Born Preterm and Survived to Two Years of Age

4.3.2Infants with Neonatal CLD

4.3.3Children with Hemodynamically Significant Congenital Heart Disease

4.3.4Children with Congenital Respiratory or Neuromuscular Diseases That Compromise Respiratory Function

4.3.5Third-Trimester Pregnant Women

4.3.6Hospitalizations for RSV Infection

4.4Forecast Methodology

4.4.1Sources Used

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods

4.5Epidemiological Forecast for RSV Infection (2014–2024)

4.5.1Risk Groups for Severe RSV Infection in Children Less than Two Years

4.5.2Preterm Births

4.5.3Neonatal CLD

4.5.4Third-Trimester Pregnant Women

4.5.5RSV Hospitalizations in Children


4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Current Treatment Options


5.2Product Profiles – RSV Prophylactics

5.2.1Synagis (palivizumab)

5.3Product Profiles – RSV Therapeutics

5.3.1Virazole (aerosolized ribavirin)

5.4Other Supportive Measures

6Unmet Needs and Opportunities


6.2Effective Therapeutic Interventions

6.2.1Unmet Need

6.2.2Gap Analysis


6.3Prophylactic Vaccines

6.3.1Unmet Need

6.3.2Gap Analysis


6.4A Prophylactic mAb with an Increased Half-Life

6.4.1Unmet Need

6.4.2Gap Analysis


6.5Point-of-care Testing for RSV in Adult Patients

6.5.1Unmet Need

6.5.2Gap Analysis


6.6Increased Awareness of RSV Infections in Adults

6.6.1Unmet Need

6.6.2Gap Analysis


7Research and Development Strategies


7.2Development of Novel Prophylactic Antibodies with Increased Cost-Effectiveness

7.3Technological Approaches to Vaccine Development

7.3.1Vaccine Antigen Selection

7.3.2Development of Maternal Vaccines

7.4Leveraging the FDA’s Fast Track Program

7.5Development of RSV Therapeutics

7.6Clinical Trial Design

7.6.1Clinical Trial Design of Key Pipeline Prophylactics

7.6.2Demonstration of Protective Efficacy for Vaccines and Prophylactic Antibodies

7.6.3Clinical Trial Design of Key Pipeline Therapeutics

7.6.4Design and Limitations of Clinical Challenge Studies

7.6.5From Challenge Studies to Demonstrating Efficacy in Naturally Infected Patients

8Pipeline Assessment


8.2Promising Drugs in Clinical Development – Prophylactic Agents

8.2.1Novavax RSV F Vaccine




8.3Promising Drugs in Clinical Development – Therapeutic Agents



8.3.3GS-5806 (presatovir)


8.4Innovative Early-Stage Approaches

9Pipeline Valuation


9.2Clinical Benchmark of Key Pipeline Products

9.2.1Prophylactic Agents

9.2.2Therapeutic Agents

9.3Commcercial Benchmark of Key Pipeline Products

9.3.1Prophylactic Agents

9.3.2Therapeutic Agents

9.4Competitive Assessment

9.4.1Prophylactic Agents

9.4.2Therapeutic Agents

9.5Top-Line 10-Year Forecast








10.4Forecasting Methodology

10.4.1RSV Patient Population Segmentation

10.4.2Percent Drug-Treated Patients

10.4.3Products Included in Each Therapeutic Class

10.4.4Launch and Patent Expiry Dates

10.4.5General Pricing Assumptions

10.4.6Individual Drug Assumptions

10.4.7Pricing of Pipeline Agents

10.5Primary Research – KOLs and Payers Interviewed for this Report



10.6Primary Research – Prescriber Survey

10.7About the Authors



10.7.3Therapy Area Director

10.7.4Global Director of Therapy Analysis and Epidemiology

10.7.5Global Head of Healthcare

10.8About GlobalData

10.9Contact Us


Frequently asked questions

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024 in real time.

  • Access a live OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) – Opportunity Analysis and Forecasts to 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.